Radionuclide venography of lower limbs by subcutaneous injection: Comparison with venography by intravenous injection

1989 ◽  
Vol 3 (3) ◽  
pp. 125-133 ◽  
Author(s):  
Chung-Chieng Wu ◽  
Shiang-Bin Jong
Keyword(s):  
Intravenous Injection ◽  
Subcutaneous Injection ◽  
Lower Limbs ◽  
Radionuclide Venography

Radionuclide Venography by Subcutaneous Injection of Tc-99m Pertechnetate at Acupuncture Point K-3: A Case Report

1994 ◽  
Vol 22 (03n04) ◽  
pp. 337-340 ◽  
Author(s):  
Ming-Feng Chen ◽  
Chung-Chieng Wu ◽  
Shiang-Bin Jong ◽  
Chun-Ching Lin
Keyword(s):  
Subcutaneous Injection ◽  
Varicose Veins ◽  
Acupuncture Point ◽  
Venous Drainage ◽  
Lower Limbs ◽  
Acupuncture Points ◽  
Collateral Flow ◽  
Left Lower Extremity ◽  
The Right ◽  
Radionuclide Venography

Recently, we developed a new method of radionuclide venography of lower limbs, namely SC-RNV, by subcutaneous injection of Tc-99m pertechnetate at acupuncture points K-3. In this study, we applied this method to evaluate the venous drainage of lower limbs in a patient with severe varicose veins and edematous swelling of the left lower extremity. For comparison, an ascending radionuclide venography by intravenous injection of Tc-99m MAA (IV-RNV) was also done. The SC-RNV showed normal venous drainage of the right side but complete obstruction of the left popliteal vein with a prominent collateral flow, compatible to the findings of IV-RNV. The findings in this case again demonstrated that SC-RNV may be useful as an alternative method of venography as previously suggested.

scholarly journals Antieosinophil serum and the kinetics of eosinophilia in Schistosomiasis mansoni.

1975 ◽  
Vol 142 (3) ◽  
pp. 560-574 ◽  
Author(s):  
A A Mahmoud ◽  
K S Warren ◽  
R C Graham
Keyword(s):  
Bone Marrow ◽  
Schistosoma Mansoni ◽  
Intravenous Injection ◽  
Peripheral Blood ◽  
Subcutaneous Injection ◽  
Host Response ◽  
Egg Laying ◽  
Schistosomiasis Mansoni ◽  
Granulomatous Lesions ◽  
Kinetics Of

Mice were exposed to different intensities of infection with Schistosoma mansoni (10, 50, or 200 cercariae) and the kinetics of peripheral and bone marrow eosinophilia was followed for as long as 20 wk. When the schistosomula (immature worms) were migrating from the lungs to the liver there was a mild, transient eosinophilia, but soon after the onset of egg laying by the schistosomes, a major and prolonged increase in eosinophils occurred. This was terminated in the heavier infections by the death of the animals, but showed a spontaneous decline beginning at 18 wk in the lightly infected mice. The effect of S. mansoni eggs on eosinophilia in the blood, bone marrow, and granulomatous lesions was then examined by injecting schistosome eggs into mice intraperitoneally, subcutaneously, and intravenously. While the host response was dependent on the route by which eggs were administered, primary peripheral and bone marrow responses were seen on intravenous injection, and secondary responses occurred on intravenous and subcutaneous injection. In unsensitized and egg-sensitized mice, eosinophils were first seen around eggs injected into the pulmonary microvasculature at 96 and 24 h respectively. When the granulomas were maximal in size eosinophils made up at least 50% of the lesions. Administration of antieosinophil serum profoundly suppressed eosinophils in the peripheral blood, eliminated mature eosinophils and markedly increased eosinophil precursors in the bone marrow, and ablated eosinophils from the tissue lesions, considerably reducing their area.

scholarly journals Comparison of Subcutaneous Injection Versus Intravenous Infusion of Cytarabine for Induction Therapy in Young Adult Acute Myeloid Leukemia: Results of a Prospective, Multicenter, Noninferiority, Randomized Trial

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 4-4
Author(s):  
Huafeng Wang ◽  
LU LIU ◽  
Jianfeng Zhou ◽  
Jianyong Li ◽  
Ying Lu ◽  
...  
Keyword(s):  
Young Adult ◽  
Blood Cell ◽  
Intravenous Injection ◽  
Induction Therapy ◽  
Intravenous Infusion ◽  
Subcutaneous Injection ◽  
De Novo ◽  
Continuous Intravenous Infusion ◽  
Injection Group ◽  
De Novo Aml

Background: Acute myeloid leukemia (AML),which is the most common type of acute leukemia, is a clonal malignant hematological disease originated from hematopoietic stem cells, characterized with blocked differentiation, excessive proliferation, organs infiltration. "3+7" regimen [anthracyclines + cytarabine (Ara-c)] is the first choice of induction chemotherapy in young adult de novo AML, and cytarabine is always given by continuous intravenous infusion. It has been reported the concentration of Ara-CTP (active metabolite with anti-leukemia effect) was higher after subcutaneous injection than during continuous intravenous infusion for about 5 hours [Liliemark JO, Semin Oncol], and the subcutaneous injection is much more convenient and inexpensive for patients comparing to continuous intravenous infusion. However, no prospective, multicenter clinical evidenceto evaluate the efficacy and safety of subcutaneous injection administration compared with intravenous infusion of cytarabine. Objective: To evaluated whether subcutaneous injection of cytarabine is noninferior to intravenous infusion of cytarabine in "3+7" induction regimen for young adult patients with de novo AML. Design, setting and participants: Open-label, prospective, multicenter, noninferior, randomized clinical trial conducted in 10 hematological centers in China. Eligible patients (n=240) with de novo AML (exclude acute promyelocytic leukemia) has been enrolled. Patients were recruited between March 2015 and August 2017, with final follow-up in June 2020. Interventions: Patients were randomized to receive idarubicin 10 mg/m2 for 3 days and cytarabine 100 mg/m2/d by continuous intravenous infusion daily for 7 days (n=120) or idarubicin 10 mg/m2 for 3 days and cytarabine 100mg/m2/d subcutaneous injection every 12 hours for 7 days (n=120). Main outcomes and measures: The primary end point was the percentage of patients who achieved complete remission (CR). The noninferiority margin for the difference in CR was -15%. Secondary end points included overall survival (OS), event-free survival (EFS) and adverse events. Results: Among 240 randomized patients, the baseline characteristics including sex, age, ECOG, white blood cell, blasts percentage, FAB subtype, karyotype and NPM1, FLTS-ITD, c-kit, CEBPA, DNMT3A, IDH1 and IDH2 mutations were similar between two groups. CR was achieved by 86 of 120 (71.7%) patients in subcutaneous injection group vs 85/120(70.8%) in intravenous injection (difference, 0.9%[1-sided 95% CI, -8.8% to ∞]); p value for noninferiority=0.003) after first cycle of induction therapy. CR was achieved by 93 of 120 (77.5%) patients in subcutaneous injection group vs 91/120(75.8%) in intravenous injection group (difference, 1.7% [1-sided 95% CI, -7.3% to ∞]); p value for noninferiority=0.001) after first two cycles of induction therapy. 3-year OS were 60% [95% CI:50%-69%]in subcutaneous injection group vs 58% [95% CI:49%-67%] in intravenous injection group (Figure 1A). After adjustment for sex, age, region, white blood cell, ECOG, platelet, FAB subtype, integrated risk and transplantation, the adjusted hazard ratio (AHR) of OS for subcutaneous vs intravenous was 0.95 [95% CI:0.62-1.47]. 3-year EFS were 49% [95% CI:39%-58%]in subcutaneous injection group vs 44% [95% CI:35%-53%] in intravenous injection group (Figure 1B). After adjustment for sex, age, region, white blood cell, ECOG, platelet, FAB subtype, integrated risk and transplantation, the HAR of EFS for subcutaneous vs intravenous was 0.84[95% CI:0.58-1.22]. No differences of hematologic toxicity, non-hematologic toxicity and early death rate were observed between two groups. Conclusions: The efficacy of subcutaneous injection of cytarabine was non inferior to continuous intravenous infusion of cytarabine for the standard induction therapy in young adult de novo AML. The toxicity is equivalent between two groups. Subcutaneous injection of cytarabine offers a convenient and inexpensive alternative therapy to young adult de novo AML. Trial registration: The trial was registered in the Chinese Clinical Trial Register, number ChiCTR-IPR-17012643. Figure 1 Disclosures No relevant conflicts of interest to declare.

scholarly journals On the Absorption of Antibodies from the Subcutaneous Tissues and Peritoneal Cavity

1907 ◽  
Vol 7 (2) ◽  
pp. 205-215 ◽  
Author(s):  
J. Henderson Smith
Keyword(s):  
Intravenous Injection ◽  
Peritoneal Cavity ◽  
Subcutaneous Injection ◽  
General Circulation ◽  
Maximum Amount ◽  
Subcutaneous Tissues ◽  
Made In

1. Antibodies in general are absorbed very slowly from the peritoneal cavity in lower animals, and from the subcutaneous tissues in man and animals. Absorption from the latter is not complete until at least 2—3 days have elapsed.2. The amount of antibody present at any one time in the general circulation after intraperitoneal or subcutaneous injection is very much less than the amount injected.3. Clinically, in urgent cases of disease, to inject antibodies subcutaneously is not only to lose 2—3 days' time before the full action can be obtained but to reduce the amount of action that the dose injected can have.4. By intravenous injection the maximum amount of action is obtained at once.The whole of the experiments recorded in this paper were made in the Statens Serum-Institut at Copenhagen, where every possible facility was given me for the carrying out of this research. To Dr Thorvald Madsen I desire to express my thanks not only for his unvarying kindliness and courtesy, but also for suggestions and assistance constantly given. I am pleased to have this opportunity of expressing my indebtedness to him.

Administration of Fractionated Heparins to Man

1979 ◽  
Author(s):  
D.A. Lane ◽  
I.R. MacGregor ◽  
G. Cella ◽  
V.V. Kakkar
Keyword(s):  
Intravenous Injection ◽  
Subcutaneous Injection ◽  
Gel Filtration ◽  
Chromogenic Substrate ◽  
Normal Volunteers ◽  
Assay Methods ◽  
Specific Activities ◽  
Heparin Preparation

A commercial mucosal heparin preparation (Leo Pharmaceuticals) has been fractionated by gel filtration into five different MW fractions of approximate mean MWs 9,500-25000. These five hep rins were randomly administered to 5 normal volunteers by intravenous and subcutaneous injection. The anticoagulant effects of the fractions were then determined by KCCT, anti-Xa clotting and anti-Xa chromogenic substrate assays. Following intravenous injection the high MW fraction produced identical elimination curves in all three assays, but with decreasing MW there was a divergence between results obtained by KCCT and anti-Xa assays. The lowest MW fraction produced between 2-3 times greater heparin levels when measured by anti-Xa assay. This divergence in assay results was not caused by the heparin induced release of an inhibitor of the Xa reaction. This was shown by performing neutral isation experiments with purified PF4 that demonstrated that both low and high MW fractions released this component, which accounted for a third of the anti-Xa heparin level. The divergent results were caused rather by the previously reported difference in specific activities when fractionated heparins were assayed in vitro by different assay methods A MW dependence was observed for the absorption of the fractions into the circulation following subcutaneous injection, with low MW heparin producing higher heparin levels determined by all the assays.

THE PREVENTIVE EFFECT OF GLUCAGON (HGF) AGAINST THE DIABETOGENIC ACTION OF ALLOXAN AND ITS ANTAGONISM BY INSULIN

1957 ◽  
Vol 15 (3) ◽  
pp. 243-247 ◽  
Author(s):  
J. L. ARTETA ◽  
A. CARBALLIDO
Keyword(s):  
Intravenous Injection ◽  
Subcutaneous Injection ◽  
Alloxan Diabetes ◽  
Preventive Effect

SUMMARY The intravenous injection of glucagon (0·4 mg/kg) 12–30 min before the administration of a diabetogenic dose of alloxan (60 mg/kg) prevents the development of alloxan diabetes in dogs. The protection obtained with glucagon is abolished by a subcutaneous injection of insulin (2 i.u./kg) administered 2 hr previously. The possible mechanism of this protection and of its antagonism by insulin is discussed.

Effects of estrogen and progesterone on pulsatile discharges of luteinizing hormone in the ovariectomized rat

1977 ◽  
Vol 55 (2) ◽  
pp. 226-233 ◽  
Author(s):  
Richard F. Weick
Keyword(s):  
Luteinizing Hormone ◽  
Intravenous Injection ◽  
Subcutaneous Injection ◽  
Ovariectomized Rats ◽  
Feedback Signal ◽  
Complete Suppression ◽  
Subcutaneous Implantation ◽  
Apparent Effect ◽  
Effective Feedback ◽  
17Β Estradiol

The effects of both acute and chronic systemic administration of estrogen and progesterone on pulsatile discharges of luteinizing hormone were observed in ovariectomized rats. Intravenous injection of 10 μg of 17β-estradiol resulted in a gradual decrease in plasma luteinizing hormone (LH) concentrations but did not completely block the pulsatile discharges. Subcutaneous implantation of Silastic capsules containing 17β-estradiol caused similar decreases; plasma LH concentrations decreased for the first 6 h but periodic increases continued, with nearly complete suppression of such pulsatile discharges by 24 h. Such inhibition was maintained for the 14-day course of the experiments. Progesterone alone, whether administered by Silastic capsule or by daily subcutaneous injection in oil, was without apparent effect on either plasma LH concentrations or temporal patterns of the hormone. Further, progesterone combined with 17β-estradiol was little, if any, more effective in this regard than estradiol alone. These results indicate that estrogen is an effective feedback signal inhibiting pulsatile release of LH in the rat and that progesterone alone has little, if any, influence in this regard.

Sign in / Sign up

Export Citation Format

Share Document